The target audience for this CME activity is primary care physicians, nurse practitioners and nurses, although many specialists also attend. These medical professionals are at the front lines of managing common endocrine conditions. To help meet their learning needs in a constantly evolving field, Ohio State's Endocrine Update provides a one-day course on diabetes management, as well as the management thyroid disorders, obesity, lipids, bone and mineral metabolism, hypogonadism, polycystic ovary syndrome and adrenal and pituitary gland disorders.
The Diabetes Dialogue is a series formulated to provide the latest breakthroughs in diabetes research and clinical practice to the medical community. Various aspects of diabetes care are presented including updates on pharmacologic and non-pharmacological intervention in the management of obesity and diabetes.
The Ohio State University Wexner Medical Center, Center for Continuing Medical Education (CCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians. Our Center for Continuing Medical Education designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The theme of this year's series is “Diabetes and Metabolic Bone Disorders.” We invite you to attend one of our sessions and learn more about the correlation between the two conditions.
- April 27, 2017: Assessing Bone Markers in Patients with Diabetes– Laura Ryan, MD
- August 31, 2017: Overview of Bone Disorders in Diabetes– Rebecca Jackson, MD
- December 14, 2017: Antidiabetic Medications and Bone Disorders– Steven Ing, MD
The 2016 theme of the Diabetes Dialogue was the often complex relationship between diabetes and cardiovascular disease.
- March 10, 2016: Update on Diabetes and Congestive Heart Failure– Philip Binkley, MD
- June 9, 2016: Cardiovascular Benefits of DPP IV Inhibitors– Benjamin O'Donnell, MD
- September 8, 2016: Cardiovascular Benefits of SGLT2 Inhibitors– David Bradley, MD
- December 8, 2016: Cardiovascular Benefits of Insulin in Diabetes– Kathleen Dungan, MD